HyperPointe’s new CEO Ezra T. Ernst began his tenure with a pair of major moves: an agency relaunch and the signing of a new account focused on helping the country move forward from the COVID-19 pandemic.

Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).

Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.